ArticlePlastic and reconstructive surgery. Global open2015
Breast Implant-associated Anaplastic Large Cell Lymphoma: Updated Results from a Structured Expert Consultation Process.
Article in Plastic and reconstructive surgery. Global open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Systematic Review of PET/CT Utilization in Breast Implant-Associated Anaplastic Large Cell Lymphoma.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Breast implant-associated late hematoma: a narrative review of case reports and case series.Gland surgery · 2026Review
- Evaluation of adipogenesis over time using a novel bioabsorbable implant without the addition of exogenous cells or growth factors.Regenerative therapy · 2024Article
- Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL).Yeungnam University journal of medicine · 2021Article
- The Breast Tumor Microenvironment: Could Silicone Breast Implant Elicit Breast Carcinoma?Breast cancer (Dove Medical Press) · 2021Article
- Breast Implant-Associated Anaplastic Large Cell Lymphoma Following Gender Reassignment Surgery: A Review of Presentation, Management, and Outcomes in the Transgender Patient Population.European journal of breast health · 2020Review
- Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin.Journal of cellular immunology · 2020Article
- Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma.Clinical case reports · 2019Article
- Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.Plastic and reconstructive surgery. Global open · 2019Article
- Breast Implant Texturization Does Not Affect the Crosstalk Between MSC and ALCL Cells.Inflammation · 2019Article
- Article
- Breast Implant-Associated Lymphoma.Deutsches Arzteblatt international · 2018Review
- Silicone-induced granuloma of breast implant capsule (SIGBIC): similarities and differences with anaplastic large cell lymphoma (ALCL) and their differential diagnosis.Breast cancer (Dove Medical Press) · 2017Review
- Article
- Novel Technique for Sampling of Breast Implant-associated Seroma in Anaplastic Large Cell Lymphoma.Plastic and reconstructive surgery. Global open · 2016Article
- Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Article
- Use ofBJR case reports · 2016Article
- Commentary on: Lymphomas Associated With Breast Implants: A Review of the Literature.Aesthetic surgery journal · 2015Article
- A review of data in medical request and the patient questionnaire for magnetic resonance evaluation of silicone breast implants.Einstein (Sao Paulo, Brazil)Article
- Breast Implant-Associated Anaplastic Large Cell Lymphoma: What We Know.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDespite increased cases published on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), important clinical issues remain unanswered. We conducted a second structured expert consultation process to rate statements related to the diagnosis, management, and surveillance of this disease, based on their interpretation of published evidence.
methodsA multidisciplinary panel of 12 experts was selected based on nominations from national specialty societies, academic department heads, and recognized researchers in the United States.
resultsPanelists agreed that (1) this disease should be called "BIA-ALCL"; (2) late seromas occurring >1 year after breast implantation should be evaluated via ultrasound, and if a seroma is present, the fluid should be aspirated and sent for culture, cytology, flow cytometry, and cell block to an experienced hematopathologist; (3) surgical removal of the affected implant and capsule (as completely as possible) should occur, which is sufficient to eradicate capsule-confined BIA-ALCL; (4) surveillance should consist of clinical follow-up at least every 6 months for at least 5 years and breast ultrasound yearly for at least 2 years; and (5) BIA-ALCL is generally a biologically indolent disease with a good prognosis, unless it extends beyond the capsule and/or presents as a mass. They firmly disagreed with statements that chemotherapy and radiation therapy should be given to all patients with BIA-ALCL.
conclusionsOur assessment yielded consistent results on a number of key, incompletely addressed issues regarding BIA-ALCL, but additional research is needed to support these statement ratings and enhance our understanding of the biology, treatment, and outcomes associated with this disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.